3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
25
Carcinoma, Hepatocellular
22
Small Cell Lung Carcinoma
17
Lung Neoplasms
14
Neoplasms
13
Breast Neoplasms
9
Colorectal Neoplasms
7
Carcinoma, Renal Cell
7
Squamous Cell Carcinoma of Head and Neck
6
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Prostatic Neoplasms
5
Melanoma
5
Carcinoma, Transitional Cell
5
Uterine Cervical Neoplasms
4
Sarcoma
4
Neoplasm Metastasis
4
Glioblastoma
4
Stomach Neoplasms
3
Solid Tumors
3
Sarcoma, Alveolar Soft Part
3
Liver Neoplasms
3
Extensive Stage Lung Small Cell Carcinoma
3
Endometrial Neoplasms
3
Carcinoma
3
Treatment-Refractory Solid Tumors
2
Small Cell Lung Cancer Extensive Stage
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Osteosarcoma
2
Interventions
atezolizumab
2
Etoposide
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Small Cell Lung Cancer Extensive Stage
×
atezolizumab
×
90 days
×
Clear all
NCT05703971
2026-06-03
Acclaim-3
Genprex, Inc.
Phase 1/2
Recruiting
62 enrolled
NCT07227597
2026-05-28
MK-6070-003
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
170 enrolled